BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21236518)

  • 1. CSF α-synuclein does not differentiate between parkinsonian disorders.
    Aerts MB; Esselink RA; Abdo WF; Bloem BR; Verbeek MM
    Neurobiol Aging; 2012 Feb; 33(2):430.e1-3. PubMed ID: 21236518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
    J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
    Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
    Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration.
    Yasui K; Inoue Y; Kanbayashi T; Nomura T; Kusumi M; Nakashima K
    J Neurol Sci; 2006 Dec; 250(1-2):120-3. PubMed ID: 17005202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cerebrospinal fluid and plasma biomarkers for dementia with lewy bodies].
    Kasuga K; Ikeuchi T
    Brain Nerve; 2012 May; 64(5):505-13. PubMed ID: 22570064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease.
    Tokuda T; Qureshi MM; Ardah MT; Varghese S; Shehab SA; Kasai T; Ishigami N; Tamaoka A; Nakagawa M; El-Agnaf OM
    Neurology; 2010 Nov; 75(20):1766-72. PubMed ID: 20962290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease.
    Tateno F; Sakakibara R; Kawai T; Kishi M; Murano T
    Alzheimer Dis Assoc Disord; 2012; 26(3):213-6. PubMed ID: 22037599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF α-synuclein as a diagnostic biomarker for Parkinson disease and related dementias.
    Ballard CG; Jones EL
    Neurology; 2010 Nov; 75(20):1760-1. PubMed ID: 20962288
    [No Abstract]   [Full Text] [Related]  

  • 13. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.
    Foulds PG; Yokota O; Thurston A; Davidson Y; Ahmed Z; Holton J; Thompson JC; Akiyama H; Arai T; Hasegawa M; Gerhard A; Allsop D; Mann DM
    Neurobiol Dis; 2012 Jan; 45(1):188-95. PubMed ID: 21856424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.
    El-Agnaf OM; Salem SA; Paleologou KE; Curran MD; Gibson MJ; Court JA; Schlossmacher MG; Allsop D
    FASEB J; 2006 Mar; 20(3):419-25. PubMed ID: 16507759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
    Holmberg B; Rosengren L; Karlsson JE; Johnels B
    Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of α-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson's disease?
    Mollenhauer B
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S76-9. PubMed ID: 24262194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
    Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
    Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
    Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
    J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.